why choose us

First received: December 7, 2022

Clinical Trial: The SLIM LIVER Study

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: HIV-1-infection
Adiposity
Insulin Resistance
Pre-diabetes
Hepatic Steatosis

Study Type: Interventional


Official Title: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of a drug called semaglutide and to see whether it can reduce IHTG. IHTG will be measured by magnetic resonance imaging (MRI; an MRI machine contains a powerful magnet that uses simple radio waves to take pictures of organs). Semaglutide (brand name Ozempic®) is a drug that is used to treat people who have diabetes; it also causes weight loss and may provide some protection against cardiovascular disease and diabetes. In PLWH, the use of…

Read more